Sanofi is a French life science company involved in research, development, manufacture and marketing of therapeutic solutions.
The company develops prevention to treatment-based products in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare segments. The company has three operating segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. Its pharmaceuticals portfolio consists of a range of prescription medicines, generic medicines and consumer health products. The company recorded sales of € 33.8 billion in 2016, a decrease by 0.7% compared to € 34 billion in 2015. The earnings per share in 2016 was € 5.68. The pharmaceutical segment revenue was recorded at € 29.2 billion. The change is due to the collaborative activities and adverse evolution of the Argentine Peso, Chinese Yuan, Mexican Peso and British Pound, which more than offset the positive effects from the Japanese Yen. The fiscal fourth quarter (Q4) sales were € 8.8 billion, an increase of 3.3% compared to 2015 Q4 sales with earnings per share at € 1.25. The pharmaceutical segment revenue recorded at Q4 was € 7.5 billion. This was driven mainly by double digit growth of the multiple sclerosis franchise (up 37.4%) and Established products (up 22.4%), in U.S. Sales in Emerging Markets increased 3.5% in the fourth quarter driven by Rare Disease (up 23.5%), Diabetes (up 4.1%), Generics (up 5.1%) and Vaccines (up 7.3%).
Strategic highlights: (Q4, 2016)
Oswaldo Cruz Foundation and the Walter Reed Army Institute of Research (WRAIR) for Zika vaccine development. (Oct)
SARIL-RA-MONARCH, a Phase 3 study, demonstrated the superiority of investigational sarilumab monotherapy versus adalimumab monotherapy in improving the clinical signs and symptoms in adults with active rheumatoid arthritis. (Nov)
LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies evaluating investigational Dupixent (dupilumab) in adult patients with atopic dermatitis (AD) met their primary endpoints. (Oct.)
Sanofi and Regeneron Pharmaceuticals received Marketing Authorization Application from EMA for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis. (Dec)
FDA approved once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection) for the treatment of adults with type 2 diabetes. (Nov)
Committee for Medicinal Products for Human Use (CHMP) of the EMA approved marketing authorization of Suliqua, basal insulin glargine for the treatment of adults with type 2 diabetes mellitus. (Nov)
Sanofi and Regeneron Pharmaceuticals received U.S. FDA’s Biologics License Applications for sarilumab, used for the treatment of adult patients with moderately to severely active rheumatoid arthritis. (Oct).
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.